1. Home
  2. APLS vs TWST Comparison

APLS vs TWST Comparison

Compare APLS & TWST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Apellis Pharmaceuticals Inc.

APLS

Apellis Pharmaceuticals Inc.

HOLD

Current Price

$23.49

Market Cap

2.7B

Sector

Health Care

ML Signal

HOLD

Logo Twist Bioscience Corporation

TWST

Twist Bioscience Corporation

HOLD

Current Price

$49.24

Market Cap

3.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
APLS
TWST
Founded
2009
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7B
3.0B
IPO Year
2017
2018

Fundamental Metrics

Financial Performance
Metric
APLS
TWST
Price
$23.49
$49.24
Analyst Decision
Buy
Buy
Analyst Count
20
9
Target Price
$32.16
$50.22
AVG Volume (30 Days)
3.9M
1.5M
Earning Date
02-27-2026
02-02-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.36
N/A
Revenue
$1,016,397,000.00
$391,557,000.00
Revenue This Year
$31.31
$16.77
Revenue Next Year
N/A
$15.06
P/E Ratio
$65.59
N/A
Revenue Growth
42.11
18.59
52 Week Low
$16.10
$23.30
52 Week High
$30.53
$54.74

Technical Indicators

Market Signals
Indicator
APLS
TWST
Relative Strength Index (RSI) 50.62 70.96
Support Level $22.29 $44.91
Resistance Level $24.10 $48.73
Average True Range (ATR) 1.18 2.57
MACD 0.15 0.32
Stochastic Oscillator 76.65 91.89

Price Performance

Historical Comparison
APLS
TWST

About APLS Apellis Pharmaceuticals Inc.

Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.

About TWST Twist Bioscience Corporation

Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.

Share on Social Networks: